Your browser is no longer supported. Please, upgrade your browser.
AZN AstraZeneca PLC daily Stock Chart
AstraZeneca PLC
Index- P/E28.63 EPS (ttm)1.19 Insider Own0.50% Shs Outstand2.53B Perf Week0.95%
Market Cap85.91B Forward P/E18.79 EPS next Y1.81 Insider Trans0.00% Shs Float2.50B Perf Month-3.25%
Income3.00B PEG2.45 EPS next Q0.38 Inst Own16.00% Short Float0.36% Perf Quarter1.62%
Sales22.47B P/S3.82 EPS this Y23.80% Inst Trans2.96% Short Ratio2.45 Perf Half Y16.68%
Book/sh5.42 P/B6.26 EPS next Y13.30% ROA6.10% Target Price39.49 Perf Year17.98%
Cash/sh2.06 P/C16.49 EPS next 5Y11.70% ROE28.00% 52W Range28.43 - 36.70 Perf YTD-2.22%
Dividend1.40 P/FCF- EPS past 5Y-17.60% ROI15.00% 52W High-7.55% Beta0.70
Dividend %4.13% Quick Ratio0.70 Sales past 5Y-7.30% Gross Margin81.60% 52W Low19.35% ATR0.69
Employees59700 Current Ratio0.90 Sales Q/Q9.40% Oper. Margin24.10% RSI (14)44.27 Volatility1.46% 1.69%
OptionableYes Debt/Eq1.30 EPS Q/Q-32.40% Profit Margin17.20% Rel Volume1.17 Prev Close34.02
ShortableYes LT Debt/Eq1.23 EarningsFeb 02 BMO Payout115.50% Avg Volume3.67M Price33.93
Recom1.60 SMA20-3.12% SMA50-1.58% SMA2001.90% Volume4,256,950 Change-0.26%
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Aug-09-17Upgrade Investec Hold → Buy
Jul-28-17Downgrade Morgan Stanley Overweight → Equal-Weight
May-12-17Upgrade Credit Suisse Underperform → Neutral
Apr-10-17Downgrade Jefferies Buy → Hold
Apr-05-17Downgrade UBS Buy → Neutral
Mar-09-17Initiated Liberum Buy
Dec-09-16Upgrade Leerink Partners Mkt Perform → Outperform
Nov-25-16Upgrade Liberum Hold → Buy
Sep-23-16Initiated Piper Jaffray Overweight
Sep-12-16Upgrade Jefferies Hold → Buy
Aug-29-16Upgrade Argus Hold → Buy
Feb-19-18 07:46PM  3 High-Yield Stocks Still Worth Buying Motley Fool
09:01AM  AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion Zacks
07:50AM  [$$] AstraZeneca hails milestone US approval for lung cancer drug Financial Times
03:48AM  AstraZeneca's immunotherapy drug wins key lung cancer approval Reuters
03:15AM  AstraZeneca's immunotherapy drug wins key lung cancer approval Reuters
02:53AM  [$$] AstraZeneca wins FDA approval for key cancer drug Financial Times
12:29AM  [$$] AstraZeneca: hoist the sales Financial Times
Feb-17-18 05:07AM  AstraZeneca's immunotherapy drug wins key lung cancer approval Reuters
Feb-16-18 05:24PM  U.S. FDA approves AstraZeneca's immunotherapy for lung cancer Reuters
Feb-12-18 05:31AM  GlaxoSmithKline plc -- Moody's: M&A greatest downside risk to European pharma companies' credit quality in 2018 Moody's
Feb-08-18 09:41AM  The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease Benzinga
Feb-06-18 09:09AM  Bristol-Myers touts lung cancer breakthrough, but critics cry foul MarketWatch
01:39AM  BNP Paribas says it posted a 'solid' 2017 despite profit slump in last quarter CNBC
Feb-05-18 08:14AM  Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint Zacks -5.91%
Feb-03-18 02:39AM  Is AstraZeneca PLC (LON:AZN) An Attractive Dividend Stock? Simply Wall St.
Feb-02-18 04:12PM  AstraZeneca's Lynparza Now 'King' Of Its Class Triumphing Over Tesaro Investor's Business Daily
12:41PM  FTSE 100 suffers worst week since April as bond yields spike MarketWatch
12:21PM  Results, risk aversion drag FTSE 100 to worst week in nine months Reuters
11:15AM  AstraZeneca flags return to drug growth in 2018, China shines Reuters
09:51AM  AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018 Zacks
06:53AM  AstraZeneca links with Alibaba and Tencent in China push Reuters
06:23AM  Astrazeneca beats 4Q profit forecasts Associated Press
05:01AM  AstraZeneca reports boost in cancer drug sales Associated Press
03:33AM  AstraZeneca profit outlook disappoints, despite drug sales growth Reuters
02:48AM  AstraZeneca flags return to drug sales growth in 2018 Reuters
Feb-01-18 05:58PM  AstraZeneca is sued by Array BioPharma over cancer drug royalties Reuters
Jan-29-18 10:51AM  AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III Zacks
09:27AM  AstraZeneca Just Scored Big On Late Stage COPD Data Market Exclusive
Jan-26-18 12:53PM  U.K. stocks rebound from 1-month low as AstraZeneca rises after trial results MarketWatch
12:04PM  Luxury-goods shares lead Europe higher as traders shake off rising euro MarketWatch
03:28AM  AstraZeneca's 3-in-1 inhaler helps COPD patients in trial Reuters
Jan-25-18 07:31AM  Novartis Receives 2 Breakthrough Therapy Designations in January Market Realist
Jan-24-18 11:54AM  Start-ups teaming up with older, larger companies to inno... CNBC Videos
07:22AM  The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca Zacks
Jan-23-18 02:40PM  Nektars Deals: AstraZeneca, Amgen, Bayer Market Realist
01:10PM  A Deeper Look at Nektar Therapeutics Licensing Agreements Market Realist
12:48PM  3 Large Cap Pharma Stocks to Beat Earnings This Quarter Zacks
10:32AM  Novartis on the Street: Analyst Ratings and Recommendations Market Realist
07:34AM  Whats Expected of Novartiss Sandoz Segment in 4Q17? Market Realist
Jan-22-18 09:42AM  AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan Zacks
08:25AM  Inside Novartiss 4Q17 Earnings: Analyst Estimates Market Realist
07:34AM  Johnson & Johnsons Consumer Segment: 4Q17 Estimates Market Realist
Jan-20-18 03:02AM  Top Picks For Pharma And Biotech Dividend Rockstars Simply Wall St.
Jan-19-18 10:23AM  Cancer Space Update: Label Expansions, Data Readouts in Focus Zacks
Jan-18-18 07:20PM  At AstraZeneca, fewer drug projects bring big productivity jump Reuters
07:10PM  At AstraZeneca, fewer drug projects bring big productivity jump Reuters
07:04PM  At AstraZeneca, fewer drug projects bring big productivity jump Reuters
04:22PM  Why This Biotech Stock Could Outperform Expectations In Lung Cancer Investor's Business Daily
Jan-17-18 03:03PM  Pieris' Artificial Protein Platform Is Undervalued By The Street, Analyst Says Benzinga
09:41AM  Nektar Boasts Strong Pipeline, Competition Remains a Woe Zacks
09:03AM  Repatha Could Significantly Drive Amgens Revenue Growth in 2018 Market Realist
Jan-16-18 04:14PM  Dow's Merck Does An About-Face, Releases Cancer Trial Results Investor's Business Daily
Jan-15-18 10:22AM  AstraZeneca's Lynparza Label Now Includes Breast Cancer Zacks
09:55AM  Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU Zacks
Jan-12-18 02:49PM  US OKs 1st drug aimed at women with inherited breast cancer Associated Press
12:45PM  LYNPARZA® (olaparib) Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer Business Wire
12:26PM  U.S. FDA approves expanded use of AstraZeneca cancer drug Reuters
11:02AM  U.S. FDA approves expanded use of AstraZeneca cancer drug Reuters
Jan-11-18 09:01AM  AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU Zacks
Jan-10-18 12:03PM  Mylans Valuation in January 2018 Market Realist
09:39AM  Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes Zacks
09:04AM  Incytes Collaborations and Developments in 4Q17 Market Realist
Jan-08-18 07:33AM  How Did Novo Nordisks NovoMix and Human Insulin Perform in 2017? Market Realist
Jan-05-18 09:05AM  How Did Novo Nordisks Victoza and Saxendra Perform in 3Q17? Market Realist
07:10AM  Wired News Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca ACCESSWIRE
Jan-04-18 08:59AM  The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez Zacks
Jan-03-18 02:12PM  Top Analyst Reports for Apple, Mastercard & 3M Zacks
Jan-02-18 04:21PM  Biotech Dives After Analyst Slashes Expectations For Cancer Drug Investor's Business Daily
07:58AM  The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S Zacks
Dec-29-17 04:20PM  These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News Investor's Business Daily
02:43PM  4 Large-Cap Pharma Stocks That Outperformed the S&P This Year Zacks
12:33PM  Tivo, travel, energy & more in the trader blitz CNBC Videos
Dec-26-17 11:13AM  Heres Why Pfizer Inc. Stock Is a Great Tax Plan Play InvestorPlace
Dec-25-17 10:30AM  What Analysts Recommend for AstraZeneca in December 2017 Market Realist
09:31AM  What Investors Should Know About AstraZeneca PLCs (LON:AZN) Financial Strength Simply Wall St.
09:00AM  What Analysts Predict for AstraZeneca Market Realist
09:00AM  Analysts Recommendations for AstraZeneca in December 2017 Market Realist
07:31AM  How AstraZenecas Other Products Portfolio Performed in 3Q17 Market Realist
07:30AM  AstraZenecas Respiratory Drugs: Pulmicort, Daliresp, and Tudorza Market Realist
Dec-22-17 10:30AM  How AstraZenecas CVMD Products Performed in 3Q17 Market Realist
10:30AM  How AstraZenecas Nexium, Synagis, and Losec Have Performed in 2017 Market Realist
09:01AM  How AstraZenecas Oncology Products Performed in 3Q17 Market Realist
09:00AM  How AstraZenecas Duaklir and Bevespi Performed in 2017 Market Realist
08:30AM  Why is Nektar (NKTR) Stock Up More Than 350% This Year? Zacks
08:02AM  Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs Zacks
07:31AM  How AstraZenecas Respiratory Products Performed in 3Q17 Market Realist
07:30AM  How Did AstraZenecas Respiratory Drug Symbicort Perform in 2017? Market Realist
Dec-21-17 11:15AM  US FDA Updates SYMBICORT Label with LABA Safety Class Revisions and Removes Boxed WARNING for Serious Asthma-Related Outcomes Business Wire
11:10AM  Why Owning Pfizer Inc. Stock Is Little Better Than Cash InvestorPlace
10:32AM  How AstraZenecas Growth Platforms Performed in 3Q17 Market Realist
10:30AM  AstraZenecas CVMD Drugs: Crestor, Seloken, and Atacand after 3Q17 Market Realist
09:02AM  How AstraZenecas Business Segments Performed in 3Q17 Market Realist
09:00AM  AstraZenecas Anti-Diabetes Drugs Onglyza and Bydureon in 2017 Market Realist
07:33AM  How AstraZenecas Revenues Trended in 3Q17 Market Realist
07:30AM  AstraZenecas Brilinta and Farxiga Posted High Growth in 3Q17 Market Realist
Dec-20-17 06:00PM  3 Dividend Stocks That Pay You More Than IBM Does Motley Fool
05:01PM  Whats AstraZenecas Valuation in December 2017? Market Realist
10:31AM  A Look at AstraZenecas Iressa, Zoladex, Casodex, and Arimidex Market Realist
09:01AM  An Overview of AstraZenecas Oncology Drug Faslodex after 3Q17 Market Realist
07:32AM  A Look at AstraZenecas Imfinzi Position after 3Q17 Market Realist
AstraZeneca PLC develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. Its marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. It has collaboration agreements with Valeant Holdings Ireland, Eli Lilly and Company, FibroGen, Astellas, Pieris Pharmaceuticals Inc, Champions Oncology, Inc., Moderna Therapeutics, Takeda Pharmaceutical Company Limited, and Chembio Diagnostics, Inc.; definitive agreement with Foundation Medicine, Inc.; a clinical trial collaboration agreement with G1 Therapeutics, Inc.; collaboration and license agreement with Celgene International Sarl; and a license agreement with LEO Pharma A/S. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.